Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EDP1815 Extension in Atopic Dermatitis
NCT05439941Phase 2Terminated
- Sponsor
- Evelo Biosciences
- Start
- Jun 2022
- Primary completion
- May 2023
- Modality
- Microbiome Therapeutics
- Countries
- 6
01
Overview
A Phase 2 trial of EDP1815 in atopic dermatitis (AD), sponsored by Evelo Biosciences. Started Jun 2022; status: terminated.
02
Drugs
EDP1815
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on NCT05439941.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05439941.